Related Experiment Video
Updated: Sep 17, 2025
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Magnolol Suppresses Osteosarcoma Progression via Apoptosis Induction and EGFR/AKT Pathway Inactivation in a U-2 OS
Chi-Huan Li1, Chia-Jung Tsai2, Fei-Ting Hsu3
1Department of Orthopedics, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Background/Aim:
Osteosarcoma is a primary malignant bone tumor with poor prognosis due to frequent metastasis and limited response to standard therapies.
Materials And Methods:
This study investigated the antitumor effects of magnolol, a bioactive compound from Magnolia officinalis, using a U-2 OS xenograft mouse model. Mice received oral magnolol (40 or 60 mg/kg/day) for 14 days. Tumor volume, histology, serum biochemistry, and immunohistochemistry were analyzed.
Results:
Magnolol significantly delayed tumor progression in a dose-dependent manner without inducing systemic toxicity. Serum aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γ-GT), and creatinine (CREA) levels, along with hematoxylin and eosin stain (H&E) staining of major organs, indicated no hepatic or renal injury. Mechanistically, magnolol up-regulated cleaved caspase-3/8/9, BAX, and BAK while down-regulating Bcl-2 and C-FLIP. Furthermore, magnolol suppressed phosphorylation of EGFR and AKT and reduced expression of Cyclin D1, MMP-9, and VEGF-A.
Conclusion:
Magnolol exerts potent anti-osteosarcoma effects by inducing apoptosis and inhibiting the EGFR/AKT signaling pathway, supporting its potential as a safe adjunctive therapy.
Insights
Magnolol, a compound from Magnolia officinalis, effectively inhibits osteosarcoma growth and metastasis in mice. This natural compound shows potential as a safe adjunctive therapy for bone cancer.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Osteosarcoma is a primary bone cancer with poor prognosis.
- Metastasis and limited treatment response are key challenges.
Purpose of the Study:
- To investigate the antitumor effects of magnolol on osteosarcoma.
- To evaluate magnolol's safety and underlying mechanisms.
Main Methods:
- A U-2 OS xenograft mouse model was used.
- Mice received oral magnolol (40 or 60 mg/kg/day) for 14 days.
- Tumor volume, histology, serum biochemistry, and immunohistochemistry were analyzed.
Main Results:
- Magnolol significantly delayed tumor progression dose-dependently without systemic toxicity.
- No hepatic or renal injury was observed.
- Magnolol induced apoptosis and suppressed EGFR/AKT signaling, reducing cell proliferation and angiogenesis markers.
Conclusions:
- Magnolol demonstrates potent anti-osteosarcoma activity by inducing apoptosis.
- Inhibition of the EGFR/AKT pathway contributes to magnolol's efficacy.
- Magnolol shows promise as a safe adjunctive therapy for osteosarcoma.
